Sotorasib and adagrasib have emerged as promising agents for precision-targeted therapy in KRAS-mutant NSCLC, with several clinical trials underway for drugs targeting KRAS G12C mutation (Skoulidis et al., 2021; Jänne et al., 2022; Hong et al., 2020; de Langen et al., 2023). This evidence concerns the gene KRAS and non-small cell lung carcinoma.